Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norcocaine is a pharmacologically active minor metabolite of cocaine, primarily formed in the liver through N-demethylation by cytochrome P-450 enzymes and FAD-containing monooxygenases. It retains central nervous system stimulant properties similar to cocaine and contributes to its overall stimulant and toxic effects, including cardiovascular, neurological, and hepatotoxic risks. Norcocaine has also been shown to possess a higher local anesthetic potential than cocaine. While not typically used recreationally, its presence in biological samples serves as a significant biomarker for recent cocaine use and metabolism, and it is often synthesized from cocaine for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norcocaine.